02:09 , Feb 17, 2018 |  BioCentury  |  Politics, Policy & Law

FDA’s bigger piggy bank

FDA plans to use a proposed record-setting funding boost to invest in projects it believes could lead to fundamental improvements in the way medical products are tested, reviewed and manufactured. The goal is to use...
23:17 , Sep 29, 2017 |  BioCentury  |  Strategy

Bridge to innovation

While Zai Lab Ltd. has joined the ranks of Chinese biotechs making a splash on NASDAQ, less noticed may be the first wave of China-based players moving into Boston to jump-start their push into novel...
20:50 , Mar 31, 2017 |  BioCentury  |  Finance

It takes two

Third Rock set up Tango Therapeutics Inc. and provided it with a $55 million A round to use advanced technologies to industrialize the discovery of targets and compounds that can induce synthetic lethality. While several...
07:00 , Jul 27, 2015 |  BioCentury  |  Strategy

Rules of competition

Competing in gene therapy is unlikely to follow the same rules as competing in other therapeutic categories where - even in Orphan diseases - a better product can steal market share. The reason is that...
07:00 , May 25, 2015 |  BioCentury  |  Finance

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone...
07:00 , Aug 15, 2011 |  BC Week In Review  |  Company News

biOasis deal

biOasis said its biOasis Advanced Technologies Inc. subsidiary acquired undisclosed IP from an undisclosed company for C$25,000 ($25,478) in cash, plus five-year warrants to purchase 350,000 shares at C$0.58 and 100,000 shares at C$0.50. If...
07:00 , Oct 1, 2009 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of schizophrenia Mice with a mutation that impairs phosphorylation of the NMDA receptor NR1 subtype (GRIN1; NR1) could help guide the development of...
07:00 , Aug 25, 2008 |  BioCentury  |  Finance

Ebb & Flow

Genentech (NYSE:DNA) disclosed in an SEC filing last week details of the retention and severance plans it has put in place to cover “substantially all” of its employees and executives as the biotech negotiates over...
08:00 , Mar 20, 2006 |  BC Week In Review  |  Company News

CombiMatrix board of directors update

CombiMatrix Corp. (CBMX), Mukilteo, Wash.   Business: Bioinformatics, Microarrays   Hired: Mansoor Mohammed as CSO of CBMX's CombiMatrix Molecular Diagnostics unit, formerly director of advanced technologies at Quest Diagnostics Inc.  ...
08:00 , Jan 16, 2006 |  BioCentury  |  Politics, Policy & Law

Let a thousand signals bloom

FDA has taken two more steps along its Critical Path with initiatives to help academic and NIH researchers validate discoveries in the clinic. The policies could address challenges posed by changes in the biotech marketplace...